# Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A

Source: https://onco.cc/trials/nct06305754/  
OnCo record `nct06305754` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sacituzumab tirumotecan, Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009). ClinicalTrials.gov record last updated 2026-09-11: active not recruiting. Enrollment is planned at 550 participants. Primary completion is estimated at 2028-08-17. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent). Registered primary measures: Overall Survival (OS).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-06
- Tags: ctgov-ingest
- Registry id: NCT06305754
- Phase: 3
- Setting: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 550

## Notes

- ClinicalTrials.gov record last updated 2026-09-11: active not recruiting. Enrollment is planned at 550 participants. Primary completion is estimated at 2028-08-17. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT06305754: https://clinicaltrials.gov/study/NCT06305754

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06305754.json